Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) EBITDA (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed EBITDA for 14 consecutive years, with -$18.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 34.04% to -$18.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$67.0 million through Dec 2025, down 41.76% year-over-year, with the annual reading at -$51.4 million for FY2025, 75.1% down from the prior year.
  • EBITDA hit -$18.9 million in Q4 2025 for Vistagen Therapeutics, up from -$19.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$6.2 million in Q1 2021 to a low of -$19.8 million in Q2 2022.
  • Historically, EBITDA has averaged -$12.4 million across 5 years, with a median of -$12.5 million in 2021.
  • Biggest five-year swings in EBITDA: crashed 288.62% in 2021 and later skyrocketed 65.09% in 2023.
  • Year by year, EBITDA stood at -$10.5 million in 2021, then increased by 7.33% to -$9.8 million in 2022, then soared by 34.98% to -$6.4 million in 2023, then tumbled by 122.05% to -$14.1 million in 2024, then plummeted by 34.04% to -$18.9 million in 2025.
  • Business Quant data shows EBITDA for VTGN at -$18.9 million in Q4 2025, -$19.4 million in Q3 2025, and -$15.1 million in Q2 2025.